LYON, France, October 15, 2012 /PRNewswire/ --
- Positive data from the MObility ImproVEments with Spasticity
in Multiple Sclerosis (MOVE) 2 study, presented at
ECTRIMS congress, supports the use of Sativex® to
reduce symptoms of moderate to severe spasticity due to multiple
sclerosis (MSS)
- The new study data shows that, after three
months, 41% of patients treated with
Sativex®, who were resistant to other
therapies, showed a clinically relevant effect
- The medicine has proven to be a cost effective treatment in
Germany, where
Almirall has already made it available as well as in Spain and Denmark
Almirall S.A. (ALM) today announces that results of the MObility
ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2
observational study performed in Germany, with 300 patients, showed that one
month's treatment with Sativex® (THC:CBD) oromucosal
spray reduces moderate to severe multiple sclerosis spasticity
(MSS) by 20% or more in 4 out of 10 patients previously
unresponsive to conventional therapies. After three months, the
improvement observed was 30% or more. Overall, 55% of the initial
patients were eligible for continuing treatment beyond the third
month.
This prospective, observational study was presented on
11th October 2012 at the
28th Congress of the European Committee for Treatment
and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France.
"An improvement on the numerical rating scale (NRS) of at
least 30% after 3 months is considered clinically relevant. For
patients, it translates into less disturbed sleep due
to MSS spasms, less pain, improved bladder
function and a greater ability to perform simple daily
activities involving mobility. These findings from everyday
clinical practice are aligned or superior to those reported in
previous clinical trials with
Sativex®, and were achieved
with slightly fewer average daily doses," commented MOVE 2 lead
investigator Professor Peter
Flachenecker, Neurological Rehabilitation Centre Quellenhof,
Bad Wildbad, Germany.
The MOVE 2 is a multicentre, prospective, observational study
including 300 adults with moderate to severe MSS treated in 42
specialised MS centres throughout Germany. Mean MS spasticity NRS scores
decreased by 25% compared to pre-treatment with
Sativex®, with 41% of patients improving at least 30%
from baseline (from 6.7 to 3.2 in this subgroup; p